First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting ...

CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...

Increasing evidence supports a link between brain ischemia and the development of Alzheimer’s disease (AD). Experimental and clinical studies have shown ...

In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while ...

EQUIGENE Therapeutics, a new spin-off biotech anchored by world-class hematology experts, marks a pivotal step in the UAE’s ...

Dr. Marty Makary noted it had "record speed approval," the fastest approval of any gene therapy device combination in U.S.

Q1 2026 earnings call recap: revenue up 16%, FY guidance raised to $192–$196M, 766 trials supported, EBITDA nearing breakeven—read now.

Grew 33% year over year within Life Sciences Services. Number of Clinical Trials Supported -- 711 as of quarter end, with 32 ...

ViQi adds a new advisor to the team in support of focusing on bioprocessing in pharma, CDMOs, and CROs. ...the need for ...

The Food and Drug Administration accepted Opus Genetics's investigational gene therapy into its Rare Disease Evidence Principles program, the company said Monday. The clinical-stage biopharmaceutical ...

National Eye Institute (NEI) scientists have found that the way the retina metabolizes glucose directly controls which genes get switched on and off in light-sensing photoreceptors. The findings ...

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...